Regeneron Pharmaceuticals Intrinsic Value – REGENERON PHARMACEUTICALS Reports Second Quarter Fiscal Year 2023 Earnings Results

🌥️Earnings Overview

On August 3 2023, REGENERON PHARMACEUTICALS ($NASDAQ:REGN) announced its earnings results for the second quarter of its fiscal year 2023, ending June 30 2023. Total revenue grew by 10.5% compared to the same quarter of the previous year, reaching USD 3158.1 million, and reported net income rose to USD 968.4 million, a 13.6% year-over-year increase.

Stock Price

The stock opened at $762.0 and closed at $771.4, representing a 5.4% increase from the stock’s closing price of $732.1 the previous day. REGENERON has seen success because of their development of current and potential treatments for a range of diseases. Their product portfolio includes treatments for cardiovascular diseases, cancer, rare diseases, infectious diseases, neurological diseases and more. They have seen success in their development of treatments for diseases such as chronic obstructive pulmonary disease (COPD) and Alzheimer’s disease.

Overall, REGENERON has reported strong financial results for the second quarter of their fiscal year 2023. The company looks forward to continuing their success in the biopharmaceutical industry with their development of treatments for a variety of diseases. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Regeneron Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Regeneron Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Regeneron Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Regeneron Pharmaceuticals are shown below. More…

Analysis – Regeneron Pharmaceuticals Intrinsic Value

GoodWhale has conducted an in-depth analysis of REGENERON PHARMACEUTICALS‘s financials. Our proprietary Valuation Line has determined the fair value of a REGENERON PHARMACEUTICALS share to be around $648.1. However, we’ve noticed that currently, the stock is trading at $771.4, a fair price that is overvalued by 19.0%. More…

Peers

The company’s competitors include Cue Biopharma Inc, CytoDyn Inc, and Belite Bio Inc.

– Cue Biopharma Inc ($NASDAQ:CUE)

The company’s market cap is $94.12M and its ROE is -48.38%. Cue Biopharma is a clinical-stage biopharmaceutical company that uses its proprietary technology to develop immuno-oncology and immuno-inflammation therapeutics. The company’s immuno-oncology product candidates are designed to target cancer cells and tumor-associated antigens. The company’s immuno-inflammation product candidates are designed to target pro-inflammatory cytokines.

– CytoDyn Inc ($OTCPK:CYDY)

CytoDyn Inc is a clinical stage biotechnology company. The company is focused on the development and commercialization of novel therapies for treating autoimmune diseases, cancer, and human immunodeficiency virus. CytoDyn’s lead product candidate is leronlimab, a monoclonal antibody that inhibits the CCR5 receptor.

Summary

REGENERON PHARMACEUTICALS reported strong financial results for Q2 2023, with total revenue up 10.5% year-over-year and net income rising 13.6%. The news was well-received by investors, causing the stock price to surge on the same day. Looking ahead, analysts are optimistic that REGENERON’s promising pipeline of new drugs and treatments will continue to buoy its financials and drive long-term growth.

Furthermore, the company’s healthy balance sheet and strong cash flow should provide further support. As such, investors may find REGENERON an attractive opportunity at current prices.